Cost-effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant staphylococcus aureus bacteremia and/or endocarditis

Clinical Infectious Diseases

Volumn 49, Issue 5, 2009, Pages 691-698

  Bhavnani, S M ^a   Prakhya, A ^a   Hammel, J P ^a   Ambrose, P G ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; GENTAMICIN; NAFCILLIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY HOSPITAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MONITORING; DRUG TREATMENT FAILURE; ENDOCARDITIS; FEMALE; HOSPITAL BED; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; FEMALE; GENTAMICINS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 70149094804     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/604710     Document Type: Article

References (14)

1. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia, recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003;82:333-339
2. Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999;179:1157-1161
3. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern Med 1991; 115:674-680
4. Small PM, Chambers HR. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-1231
5. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59
6. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-665
7. The red book. Montvale, NJ: Thomson Healthcare, 2006.
8. Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm 2007; 64:1080-1086 (Pubitemid 46801540)
9. Paladino JA, Gudgel LD, Forrest. A, Neiderman MS. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122:1271-1279 (Pubitemid 35339540)
10. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from I.V. to oral. Am J Health Syst Pharm 2002;59:2209-2215 (Pubitemid 35315724)
11. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-1448
12. Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP. Cost comparison of single daily IV doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health Syst Pharm 1997;54:1614-1618 (Pubitemid 27306706)
13. Hatoum HT. Microcost analysis of inpatient dispensing and administration of oral solids. Am J Hosp Pharm 1990;47:800-805
14. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-1336